Biogen vs Zocdoc

Side-by-side comparison of AI visibility scores, market position, and capabilities

Zocdoc leads in AI visibility (86 vs 78)
Biogen logo

Biogen

LeaderHealthcare Tech

Enterprise

Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.

AI VisibilityBeta
Overall Score
B78
Category Rank
#42 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
81
Gemini
83

About

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.

Full profile
Zocdoc logo

Zocdoc

GrowthHealthTech

Patient Scheduling Marketplace

Zocdoc is a patient appointment booking marketplace that lets patients find and book in-network doctors in real time, with insurance verification and same-day availability filters.

AI VisibilityBeta
Overall Score
A86
Category Rank
#11 of 596
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
80
Gemini
92

About

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Patients can filter by specialty, insurance plan, location, and next available appointment, then book online in seconds — eliminating the phone-tag and hold-time historically required to schedule care. The platform verifies insurance acceptance in real time and sends automated reminders to reduce no-shows.

Full profile

AI Visibility Head-to-Head

78
Overall Score
86
#42
Category Rank
#11
72
AI Consensus
70
stable
Trend
stable
82
ChatGPT
88
81
Perplexity
80
83
Gemini
92
72
Claude
92
76
Grok
86

Key Details

Category
Enterprise
Patient Scheduling Marketplace
Tier
Leader
Growth
Entity Type
company
brand

Capabilities & Ecosystem

Capabilities

Only Zocdoc
Patient Scheduling Marketplace

Integrations

Only Biogen
Biogen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.